{"paper_id":"18446dd2-f359-4c33-8720-0731df7b5ef8","body_text":"Zusammenfassung\nDie primäre Dysmenorrhö tritt besonders häufig bei Jugendlichen bis zum 20. Lebensjahr auf. Sie beruht meist nicht auf pathologischen Organveränderungen. Die sekundäre Dysmenorrhö wird erst später erworben und ist bei Jugendlichen am häufigsten Symptom einer Endometriose oder anatomischer Fehlbildungen. Daher spielt die rechtzeitige Abklärung der sekundären Dysmenorrhö eine wichtige gesundheitspräventive Rolle. Die Endometriose ist bei Jugendlichen zumeist minimal oder mild ausgeprägt. Daher ist ein medikamentöser Therapieversuch mit NSAID und/oder oralen Kontrazeptiva gerechtfertigt. Ein Nichtansprechen der Beschwerden auf eine 3- bis 6-monatige medikamentöse Therapie sollte zur weiteren Abklärung veranlassen. Das Therapieziel ist die frühzeitige Erkennung von Organpathologien und die Minimierung von Dysmenorrhö und Beckenschmerzen, primär mit medikamentöser Langzeitbehandlung.\nAbstract\nPrimary dysmenorrhea is especially frequent in adolescents until 20 years of age, and is usually without pelvic pathology. Secondary dysmenorrhea is acquired later, and in adolescents is most often due to endometriosis or reproductive tract anomalies. Therefore, a timely evaluation of the etiology of secondary dysmenorrhea plays an important role in preventive health care. Endometriosis in adolescents is mostly minimal or mild. For this reason, initial conservative treatment with NSAID and/or oral contraceptives is justified. If the symptoms do not respond to medical therapy within 3–6 months, further diagnostic measures are indicated. The therapeutic goal is the early recognition of pelvic pathology and maximum reduction of dysmenorrhea and pelvic pain, primarily based on long-term medical treatment.\nSimilar content being viewed by others\nLiteratur\nAndersch B, Milsom I (1982) An epidemiologic study of young women with dysmenorrhea. Am J Obstet Gynecol 144: 655–660\nAnthuber S, Strauss A, Anthuber C, Hepp H (2003) Fehlbildungen des äußeren und inneren Genitales. Gynäkol Geburtsh Rundsch 43: 136–145\nAttaran M, Gidwani GP (2003) Adolescent endometriosis. Obstet Gynecol Clin N Am 30: 379–390\nBai SW, Cho HJ, Kim JY et al. (2002) Endometriosis in an adolescent population: the severance hospital in Korean experience. Yonsei Med J 43: 48–52\nBieglmayer C, Hofer G, Kainz C, Reinthaller A, Kopp B, Janisch H (1995) Concentrations of various arachidonic acid metabolites in menstrual fluid are associated with menstrual pain and are influenced by hormonal contraceptives. Gynecol Endocrinol 9: 307–312\nBrucker C (2004) Medikamentöse Therapie der Endometriose. Gynäkologe: (im Druck)\nChan WY, Hill JC (1978) Determination of menstrual prostaglandin levels in non-dysmenorrheic and dysmenorrheic subjects. Prostaglandins 15: 365–375\nChan WY, Dawood MY (1980) Prostaglandin levels in menstrual fluid of nondysmenorrheic and of dysmenorrheic subjects with and without oral contraceptive or ibuprofen therapy. Adv Prostaglandin Thromboxane Res 8: 1443–1447\nDaniels SE, Talwalker S, Torri S, Snabes MC, Recker DP, Verburg KM (2002) Valdecoxib, a cyclooxygenase-2-specific inhibitor, is effective in treating primary dysmenorrhea. Obstet Gynecol 100: 350–358\nDavis AR, Westhoff CL (2001) Primary dysmenorrhea in adolescent girls and treatment with oral contraceptives. J Pediatr Adolesc Gynecol 14: 3–8\nDuRant RH, Jay MS, Shofitt T (1985) Factors influencing adolescents‘ responses to regimens of naproxen for dysmenorrhea. Am J Dis Child 139: 489–493\nEkstrom P, Juchnicka E, Laudanski T, Akerlund M (1989) Effect of an oral contraceptive in primary dysmenorrhea: changes in uterine activity and reactivity to agonists. Contraception 40: 39–47\nEkstrom P, Akerlund M, Forsling M, Kindahl H, Laudanski T, Mrugacz G (1992) Stimulation of vasopressin release in women with primary dysmenorrhea and after oral contraceptive treatment—effect on uterine contractility. Br J Obstet Gynaecol 99: 680–684\nGambone JC, Mittman GS, Munro MG, Scialli AR, Winkel CA, and the Chronic Pelvic Pain/Endometriosis Working Group (2002) Consensus statement for the management of chronic pelvic pain and endometriosis: proceedings of an expert-panel consensus process. Fertil Steril 78: 961–972\nGoldstein DP, DeCholnoky C, Leventhal JM, Emans SJ (1979) New insights into the old problem of chronic pelvic pain. J Pediatr Surg 14: 675–680\nHanson FW, Izu A, Henzyl MR (1978) Naprosyn sodium in dysmenorhea: its influence in allowing work/school activities. Obstet Gyncecol: 52: 583–587\nHarel Z (2002) A contemporary approach to dysmenorrhea in adolescents. Paediatr Drugs 4: 797–805\nJohnson J (1988) Level of knowledge among adolscent girls regarding effective treatment for dysmenorrhea. J Adolesc Health 9: 398–402\nLaufer MR, Goitein L, Bush M, Cramer DW, Emns SJ (1997) Prevalence of endometriosis in adolescent girls with chronic pelvic pain not responding to conventional therapy. J Pediatr Adolesc Gyncecol 10: 199–202\nLundstrom V, Green K (1978) Endogenous levels of prostaglandin F2α and its main metabolites in plasma and endometrium of normal and dysmenorrheic women. Am J Obstet Gynecol 130: 640–646\nMarchini M, Tozzi L, Bakshi R, Pistai R, Fedele L (1995) Comparative efficacy of diclofenac dispersible 50 mg and ibuprofen 400 mg in patients with primary dysmenorrhea. A randomized, double-blind, within-patient, placebo-controlled study. Int J Clin Pharmacol Ther 33: 491–497\nMehlisch DR (1988) Ketoprofen, ibuprofen, and placebo in the treatment of primary dysmenorrhea: a double-blind crossover comparison. J Clin Pharmacol 28: 29–33\nMehlisch DR (1990) Double-blind crossover comparison of ketoprofen, naproxen, and placebo in patients with primary dysmenorrhea. Clin Ther 12: 398–409\nMilsom I, Andersch B (1984) Effect of various oral contraceptive combinations on dysmenorrhea. Gynecol Obstet Invest 17: 284–292\nMilsom I, Minic M, Dawood MY, Akin MD, Spann J, Niland NF, Squire RA (2003) Comparison of the efficacy and safety of nonprescription doses of naproxen and naproxen sodium with ibuprofen, acetaminophen, and placebo in the treatment of primary dysmenorrhea. A pooled analysis of five studies. Clin Therapeut 24: 1384–1400\nMorrison BW, Daniels SE, Kotey P, Cantu N, Seidenberg B (1999) Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial. Obstet Gynecol 94: 504–508\nOlive DL, Pritts EA (2001) Treatment of endmetriosis. NEJM 345: 266–275\nProctor ML, Murphy PA (2003) Herbal and dietary therapies for primary and secondary dysmenorrhea. Cochrane Database of Systematic Reviews 1\nReese KA, Reddy S, Rock JA (1996) Endometriosis in an adolescent population: the Emory experience. J Pediatr Adolesc Gynecol 9: 125–128\nRoy S (1983) A double-blind comparison of a propinoic acid derivative (ibuprofen) and a fenamate (mefenamic acid) in the treatment of dysmenorrhea. Obstet Gynecol 61: 628–632\nSimopoulos AP (1991) Omega-3 fatty acids in health and disease and in growth and development. Am J Clin Nutr 54: 438–463\nSimpson JL, Elias S, Malinak LR, Buttram VC Jr (1980) Heritable aspects of endometriosis (I). Genetic studies. Am J Obstet Gynecol 137: 327–331\nSlap GB (2003) Menstrual disorders in adolescence. Best Pract Res Clin Obstet Gynaecol 17: 75–92\nWeber-Diehl F, Unger R, Lachnit U (1992) Triphasic combination of ehtinyl estradiol and gestodene: long-term clinical trial. Contraception 46: 19–27\nZahradnik HP, Breckwoldt M (1984) Contribution to the pathogenesis of dysmenorrhea. Arch Gynecol, 236: 99–108\nZahradnik HP (1984) Der Wirkungsmechanismus von Dydrogesteron bei Dysmenorrhö. Prostaglandin-Spiegel im Menstrualblut. Fortschr Med 102: 439–442\nZiaei S, Faghihzadeh S, Sohrabvand F, Lamyian M, Emamgholy T (2001) A randomised placebo-controlled trial to determine the effect of vitamin E treatment of primary dysmenorrhea. BJOG 108: 1181–1183\nInteressenkonflikt:\nDer korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen.\nAuthor information\nAuthors and Affiliations\nCorresponding author\nRights and permissions\nAbout this article\nCite this article\nBrucker, C., Buck, G. Dysmenorrhö bei Jugendlichen. Gynäkologische Endokrinologie 2, 70–76 (2004). https://doi.org/10.1007/s10304-004-0058-5\nIssue date:\nDOI: https://doi.org/10.1007/s10304-004-0058-5\nSchlüsselwörter\n- Primäre Dysmenorrhö\n- Sekundäre Dysmenorrhö\n- Gesundheitsprävention\n- Abklärung\n- Medikamentöse Langzeitbehandlung","source_license":"CC0","license_restricted":false}